This inventor holds 1 USPTO granted patent. Top assignee: Development Center for Biotechnology. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Shou-Chung Chao: Innovator in Biodegradable Drug Delivery Systems
Introduction
Shou-Chung Chao is a notable inventor based in Taipei County, Taiwan. He has made significant contributions to the field of drug delivery systems, particularly through his innovative work on biodegradable implants. His research focuses on enhancing the efficacy and longevity of drug release in medical applications.
Latest Patents
One of Shou-Chung Chao's key inventions is a patent for a sustained release implant for granisetron. The main goals of this invention are to develop a long-term release of granisetron injection implant composition using biodegradable polymers and to refine the processing methods involved. Granisetron is combined with various biodegradable polymers, and a hot melt extrusion technique is employed, utilizing different diameters, temperatures, extrusion rates, and holding times to create the implant. In vitro dissolution studies of the granisetron injection implant composition demonstrate that the drug is released continuously for over seven days.
Career Highlights
Shou-Chung Chao is affiliated with the Development Center for Biotechnology, where he applies his expertise in drug delivery systems. His work has been instrumental in advancing the field of biodegradable implants, which hold promise for improving patient outcomes in various medical treatments.
Collaborations
Some of his notable coworkers include Paonien Chan and Shu-Chien Liu, who have collaborated with him on various projects related to drug delivery and biodegradable materials.
Conclusion
Shou-Chung Chao's innovative work in the development of biodegradable drug delivery systems highlights his commitment to advancing medical technology. His contributions, particularly in the sustained release of granisetron, showcase the potential for improved therapeutic outcomes through innovative engineering solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
